What is Blaze Bioscience?
Blaze Bioscience is a privately held biotechnology firm dedicated to improving cancer care, with a particular focus on pediatric brain cancer surgery. The company leverages its proprietary Tumor Paint technology alongside the CANVAS imaging system to enhance the precision of cancer detection, surgical removal, and subsequent treatment. Their mission centers on making cancer care more sensitive, reliable, and accessible for healthcare providers and institutions.
How much funding has Blaze Bioscience raised?
Blaze Bioscience has raised a total of $17M across 7 funding rounds:
Debt
$725K
Series A
$5M
Series B
$9M
Debt
$991K
Debt
$554K
Debt
$350K
Debt
$421K
Debt (2011): $725K, investors not publicly disclosed
Series A (2012): $5M, investors not publicly disclosed
Series B (2013): $9M, investors not publicly disclosed
Debt (2015): $991K, investors not publicly disclosed
Debt (2017): $554K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Debt (2021): $421K led by PPP
What's next for Blaze Bioscience?
The substantial enterprise-level funding Blaze Bioscience has attracted indicates a strong market validation and positions the company for significant scaling and further technological development. This strategic backing is likely to accelerate the commercialization of its Tumor Paint and CANVAS technologies, potentially expanding its reach into broader oncology applications and solidifying its role as a key innovator in the medical technology sector. Future growth may involve strategic partnerships and expanded clinical trials to further validate and broaden the application of their cancer-detection and treatment solutions.
See full Blaze Bioscience company page
